SCHEMBL3768291

SCHEMBL3768291

Cc1ccc(N2CCN(CC(=O)N3CCN(C4CCCCC4)CC3)CC2)c(C)c1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.49
GAA P10253 1/20 0.49
ALOX12 P18054 1/20 0.49
LMNA P02545 4/20 0.47
HTT P42858 4/20 0.47
POLB P06746 2/20 0.47
TSHR P16473 4/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
TP53 P04637 1/20 0.45
ALOX15 P16050 1/20 0.45
MAPK1 P28482 1/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 3/20 0.45
NPSR1 Q6W5P4 1/20 0.45
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3763252 0.99 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2GAAALOX12LMNA
SCHEMBL3767940 0.97 SMN1; SMN2 (0.50) ALDH1A1SMN1; SMN2GAAALOX12LMNA
SCHEMBL3777128 0.91 SMN1; SMN2 (0.60) ALDH1A1SMN1; SMN2GAAALOX12LMNA
SCHEMBL3767667 0.90 SMN1; SMN2 (0.61) ALDH1A1SMN1; SMN2GAAALOX12LMNA
SCHEMBL3772241 0.88 SMN1; SMN2 (0.61) ALDH1A1SMN1; SMN2GAAALOX12LMNA
SCHEMBL20122620 0.87 TSHR (0.58) ALDH1A1POLBTSHRMEN1KMT2A
SCHEMBL3763088 0.87 TSHR (0.58) ALDH1A1POLBTSHRMEN1KMT2A
SCHEMBL3774214 0.85 TSHR (0.56) ALDH1A1HTTPOLBTSHRMEN1
SCHEMBL3767518 0.84 LMNA (0.57) ALDH1A1SMN1; SMN2LMNAHTTMEN1
SCHEMBL3767997 0.83 TSHR (0.53) ALDH1A1POLBTSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 ALDH1A1 1210/4885SMN1; SMN2 4282/4885GAA 2143/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.